Nifty
:
21995.85
Sensex
:
72488.99
-152.05 (-0.69%)
-454.69 (-0.62%)
Nifty
Sensex
:
:
21995.85
72488.99
-152.05 (-0.69%)
-454.69 (-0.62%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
64/99

BSE: 532296 | NSE: GLENMARK

NSE BSE
1041.80
18-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1060.00
  •  1063.95
  •  1034.20
  •  1060.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1139829
  •  11935.80
  •  1070.00
  •  500.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 29,423.76
  • N/A
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 33,220.75
  • 0.24%
  • 3.37

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.64%
  • 2.46%
  • 14.83%
  • FII
  • DII
  • Others
  • 21.38%
  • 12.84%
  • 1.85%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.13
  • 5.66
  • 5.88

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.64
  • 7.52
  • 1.80

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -5.84
  • -20.31
  • -32.58

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.39
  • 14.22
  • 13.95

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.86
  • 1.89
  • 1.86

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.20
  • 8.40
  • 8.45

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
2,506.70
3,100.18
-19.14%
3,207.38
3,017.93
6.28%
3,401.60
2,777.29
22.48%
3,373.72
3,019.15
11.74%
Expenses
2,715.35
2,626.14
3.40%
2,745.09
2,538.96
8.12%
2,770.39
2,345.69
18.11%
2,768.75
2,555.75
8.33%
EBITDA
-208.65
474.04
-
462.28
478.97
-3.48%
631.21
431.60
46.25%
604.97
463.40
30.55%
EBIDTM
-8.32%
15.29%
14.41%
15.87%
18.56%
15.54%
17.93%
15.35%
Other Income
45.41
70.56
-35.64%
1.70
86.35
-98.03%
20.87
183.16
-88.61%
-40.21
107.20
-
Interest
134.34
97.11
38.34%
121.46
82.94
46.44%
112.00
59.99
86.70%
109.26
86.85
25.80%
Depreciation
147.07
151.51
-2.93%
141.45
145.77
-2.96%
154.65
146.75
5.38%
146.53
131.52
11.41%
PBT
-521.38
329.86
-
-124.35
336.62
-
333.41
408.01
-18.28%
-490.77
269.69
-
Tax
-71.80
144.09
-
55.95
164.83
-66.06%
160.28
196.91
-18.60%
-87.63
97.13
-
PAT
-449.58
185.77
-
-180.30
171.79
-
173.13
211.11
-17.99%
-403.14
172.57
-
PATM
-17.94%
5.99%
-5.62%
5.69%
5.09%
7.60%
-11.95%
5.72%
EPS
-12.45
9.66
-
-2.90
9.23
-
5.31
6.82
-22.14%
-15.18
5.51
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
12,489.40
12,990.11
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
5,944.95
Net Sales Growth
4.82%
5.57%
12.44%
2.85%
7.86%
8.72%
-0.05%
20.07%
13.18%
12.38%
 
Cost Of Goods Sold
4,650.15
4,453.84
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
1,785.62
Gross Profit
7,839.25
8,536.27
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
4,159.33
GP Margin
62.77%
65.71%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
69.96%
Total Expenditure
10,999.58
10,711.74
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
4,854.17
Power & Fuel Cost
-
227.52
200.64
164.67
173.69
165.25
137.47
127.02
120.47
109.11
93.50
% Of Sales
-
1.75%
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
1.57%
Employee Cost
-
2,780.96
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
1,026.15
% Of Sales
-
21.41%
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
17.26%
Manufacturing Exp.
-
770.68
784.63
638.74
669.50
725.16
648.59
546.75
956.59
1,323.66
336.59
% Of Sales
-
5.93%
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
5.66%
General & Admin Exp.
-
1,266.05
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
491.20
253.29
859.67
% Of Sales
-
9.75%
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
14.46%
Selling & Distn. Exp.
-
1,154.10
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
524.25
% Of Sales
-
8.88%
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
8.82%
Miscellaneous Exp.
-
58.59
78.68
121.44
47.19
33.29
314.55
88.52
38.82
38.48
524.25
% Of Sales
-
0.45%
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
3.84%
EBITDA
1,489.81
2,278.37
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
1,090.78
EBITDA Margin
11.93%
17.54%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
18.35%
Other Income
27.77
316.79
166.67
50.22
159.60
208.14
91.40
37.37
20.00
6.88
11.48
Interest
477.06
349.58
298.10
353.11
377.32
334.58
285.57
237.32
178.88
190.15
188.59
Depreciation
589.70
611.27
486.71
443.55
417.17
325.90
301.88
264.37
234.28
300.41
216.79
PBT
-803.09
1,634.31
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
696.88
Tax
56.80
491.05
447.60
412.39
320.11
375.64
315.46
382.68
300.94
334.07
151.27
Tax Rate
-7.07%
56.54%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
21.71%
PAT
-859.89
297.24
941.71
970.04
775.97
924.98
803.78
1,108.80
743.23
209.54
542.27
PAT before Minority Interest
-949.19
377.40
993.65
970.09
775.97
924.99
803.87
1,108.75
743.04
209.47
545.60
Minority Interest
-89.30
-80.16
-51.94
-0.05
0.00
-0.01
-0.09
0.05
0.19
0.07
-3.33
PAT Margin
-6.88%
2.29%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
9.12%
PAT Growth
-216.01%
-68.44%
-2.92%
25.01%
-16.11%
15.08%
-27.51%
49.19%
254.70%
-61.36%
 
EPS
-30.47
10.53
33.37
34.37
27.50
32.78
28.48
39.29
26.34
7.43
19.22

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
9,473.92
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
2,983.28
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
27.13
27.12
Total Reserves
9,428.09
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
2,956.16
Non-Current Liabilities
2,680.97
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
1,966.58
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
2,428.66
Unsecured Loans
3,852.14
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
5,045.53
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
2,949.17
Trade Payables
2,391.86
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
1,362.58
Other Current Liabilities
1,690.55
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
973.31
Short Term Borrowings
350.00
370.00
513.01
442.60
303.02
295.04
187.19
787.42
347.60
353.32
Short Term Provisions
613.12
584.50
564.45
555.91
484.11
432.46
262.95
134.03
216.78
259.95
Total Liabilities
17,565.76
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
7,912.31
Net Block
6,202.39
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
2,889.66
Gross Block
11,296.06
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
3,632.62
Accumulated Depreciation
5,093.68
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
742.96
Non Current Assets
7,692.04
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
3,149.61
Capital Work in Progress
1,251.26
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
206.24
Non Current Investment
44.65
49.62
24.63
24.59
29.66
14.66
15.69
17.20
17.12
0.00
Long Term Loans & Adv.
190.29
161.38
146.29
123.97
94.36
119.78
98.94
69.99
468.16
33.39
Other Non Current Assets
3.46
6.70
27.89
26.49
15.80
0.56
0.13
0.16
0.27
20.33
Current Assets
9,873.72
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
4,762.69
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,977.79
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
932.88
Sundry Debtors
4,098.61
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
2,156.34
Cash & Bank
1,469.70
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
800.67
Other Current Assets
1,327.62
297.46
671.05
603.30
1,312.40
1,391.61
1,273.61
986.77
774.38
872.81
Short Term Loans & Adv.
966.86
972.41
700.49
544.48
547.18
580.83
590.22
594.89
742.94
768.44
Net Current Assets
4,828.19
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
1,813.53
Total Assets
17,565.76
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10
7,912.30

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
625.39
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
853.73
PBT
868.45
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
696.88
Adjustment
1,471.96
787.11
644.82
636.23
329.83
571.28
726.56
391.03
522.76
709.78
Changes in Working Capital
-1,074.48
-561.26
-385.84
127.06
136.34
309.06
-861.51
-611.96
-266.82
-290.07
Cash after chg. in Working capital
1,265.93
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
1,116.58
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-640.54
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
-262.86
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-528.49
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
-368.10
Net Fixed Assets
-220.67
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
-112.12
Net Investments
-1,774.62
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
-114.91
Others
1,466.80
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
-141.07
Cash from Financing Activity
-77.46
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
698.60
199.22
-98.02
Net Cash Inflow / Outflow
19.45
254.88
14.20
164.23
-113.56
166.21
488.24
163.27
140.86
387.61
Opening Cash & Equivalents
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
605.18
Closing Cash & Equivalent
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
335.13
321.45
249.60
214.65
198.27
182.62
159.16
128.59
65.74
109.99
ROA
2.29%
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
7.51%
ROE
4.07%
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
18.99%
ROCE
9.17%
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
15.04%
Fixed Asset Turnover
2.76
2.94
2.97
1.44
1.66
1.80
2.03
1.96
1.90
1.83
Receivable days
44.33
37.24
36.01
78.95
83.73
94.95
97.29
119.39
125.97
115.37
Inventory Days
33.73
31.35
31.90
75.25
79.22
83.59
73.65
67.68
59.42
53.99
Payable days
191.79
191.57
219.98
98.44
97.43
96.28
101.59
117.03
95.22
83.15
Cash Conversion Cycle
-113.73
-122.98
-152.06
55.77
65.53
82.26
69.35
70.04
90.17
86.21
Total Debt/Equity
0.46
0.40
0.67
0.80
0.80
0.90
1.05
1.10
2.13
1.10
Interest Cover
3.48
5.83
4.92
3.90
4.89
4.92
7.28
6.84
3.86
4.70

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Glenmark Pharma - Quarterly Results
    13th Feb 2024, 13:38 PM

    Read More
  • Glenmark Pharmaceuticals partners with Pfizer to launch Abrocitinib in India
    31st Jan 2024, 18:03 PM

    Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization in India

    Read More
  • Glenmark, Ichnos launch alliance to accelerate new drug discovery in cancer treatment
    30th Jan 2024, 17:35 PM

    The newly formed IGI features a robust pipeline of three innovative oncology molecules targeting multiple myeloma, acute myeloid leukemia and solid tumors currently undergoing clinical trials

    Read More
  • Glenmark Pharmaceuticals’ arm signs license agreement with Jiangsu Alphamab, 3DMed
    25th Jan 2024, 09:20 AM

    GSSA will receive from Jiangsu Alphamab and 3DMed, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.